Association Between CytochromeP4501A2 and CytochromeP4502E1 Gene Polymorphisms and Metabolism of Theophylline

Association Between CytochromeP4501A2(CYP1A2) and CytochromeP4502E1(CYP2E1) Gene Polymorphisms and Metabolism of Theophylline in a Chinese Population

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02001935

Enrollment

102

Registered

2013-12-05

Start date

2013-09-30

Completion date

2014-07-31

Last updated

2014-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD, theophylline, CYP1A2, CYP2E1

Brief summary

The aim of this study is to determine whether common CYP1A2 and CYP2E1 gene polymorphisms effect metabolism of theophylline in chronic obstructive pulmonary disease patients.

Interventions

DRUGtheophylline

After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Aged 18-75 years,COPD patients, male or female; * regularly visiting our hospital; * taking a sustained-release preparation of theophylline continuously for at least 2 weeks

Exclusion criteria

* patients with renal or hepatic dysfunction; * patients with congestive heart failure; * patients with hypothyroidism or hyperthyroidism; * patients currently taking drugs likely to affect theophylline metabolism or who had taken such drugs in the preceding week; * patients with extreme obesity * patients with very severe Chronic Obstructive Pulmonary Disease(COPD)

Design outcomes

Primary

Measure	Time frame	Description
Theophylline clearance	Blood samples will be taken after receiving oral thoephylline for 14 days	Theophylline and it's metabolite(1,3-dimethyluric) blood concentration

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026